Background: Oral multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (IO), have increased survival of patients with metastatic renal cell carcinoma (mRCC). Common sites of mRCC are lymph nodes, lung, liver and bone, but some unexpected clinical presentations sometime occurred as cardiac metastasis without validated treatment. We described a case report of a patient presenting cardiac metastasis treated with IO who showed a dramatic, durable response, which was prolonged despite stopping the drug.
Introduction
A major breakthrough for patients with metastatic renal cell carcinoma (mRCC) has been observed during this past decade. Currently approved targeted agents include the oral multitargeted tyrosine kinase inhibitors (TKIs) sunitinib, pazopanib, cabozantinib and axitinib [1] [2] [3] [4] ; immune checkpoint inhibitors (IO) anti-PD-1 nivolumab [5] , anti-CTLA4 ipilimumab [6] and the mammalian target of rapamycine kinase inhibitors everolimus, and tesmirolimus [7] .
Common sites of RCC metastases are lymph nodes, lung, liver and bone. In addition, natural history with prolonged survival has changed under treatment pressure, with the onset of most frequent brain or pancreatic metastases or unexpected presentation as in our clinical case. Although cardiac involvement via the inferior vena cava (IVC) thrombi is well-known, cardiac metastasis in RCC is a rare event with only a few cases reported worldwide and no validated treatment. Because of the high risk of sudden death, specific multi-disciplinary management is required.
Case presentation
In July 2008, a 51-year-old male patient with no significant medical history was diagnosed with a locally advanced clear cell renal cell (CCRC) carcinoma that was treated by radical nephrectomy and hepatic segmentectomy, due to contiguity. Eleven months later the patient developed two single lung and liver metastases, for which a systemic 
Discussion
Cardiac metastases from RCC are considered to be rare. Currently, two series of autopsies have shown an incidence ranging from 1 to 7% [8] [9] . The extension of mRCC to the heart is usually associated with inferior vena cava (IVC) involvement, occurring in 4 to 10% of cases especially in advanced disease [10] . At present radical surgery represents the only chance of long-term survival for patients with RCC and tumour thrombus extension into the vena cava, with a median survival of 19.8 months for patients who underwent surgery compared to 6.9 months for patients who did not [11] . Only limited data has so far been reported as to the efficacy of TKIs, alone or combined with surgery, in the context of IVC thrombus extension. In a small French retrospective serie of 14 patients, neoadjuvant TKIs (with either sunitinib or sorafenib) failed to demonstrate a significant impact on surgical management of RCC with IVC involvement [12] , with respectively 12 cases (85%) of stable thrombi and one case (7%) of thrombus progression. In addition, a multi-institutional review of 25 patients treated with TKIs before surgery showed a minimal cytoreductive effect on RCC tumor thrombi [13] , with no clear clinical relevance. Only one case (4%) of tumour thrombus regression potentially affected the surgical approach.
Despite the frequency of renal tumors with IVC and atrial thrombi, little is known about cardiac metastases from RCC with only a limited number of cases reported in the literature. Cardiac metastases from RCC seem to occur through two mechanisms, including the venous hematogenous pathway and lymphatic pathway [14] . In a recent systematic review of reported clinical cases from 1973 to 2015, the analysis of 39 RCC patients with cardiac metastases without IVC involvement highlighted the poor outcomes [15] . With regard to specific medical management, 30.8% (12/39) of patients received systemic therapy, of whom 82% received VEGF targeted agents.
Out of these 12 patients, partial responses were documented in five patients (12.8%), two of whom received TKI sunitinib, and stable disease was reported in one patient treated with sunitinib. Karakiewicz et al. reported a neoadjuvant setting using sunitinib to downstage an atrial thombus [16] . No case of systemic treatment with IO blocker has been reported.
To our knowledge, we report the first case of an IO blocker response on cardiac metastases in the context of metastatic RCC. In addition, immunotherapy efficacy was maintained over time, even after treatment discontinuation and regardless of metastasis localization. Targeted therapies and systemic treatments including immune checkpoint blockers of mRCC have never been assessed in the context of cardiac metastases without IVC involvement and further studies and observations are warranted to understand the mechanism of action and specific aspects of this entity.
Conclusion
In summary, this case illustrates the major role of immune checkpoint blocker efficacy on an uncommon metastasis with a durable response, even in the case of treatment discontinuation. 
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